U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C50H66Cl4N8O10S2
Molecular Weight 1145.0525
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TENAPANOR

SMILES

CN1C[C@@]([H])(c2cccc(c2)S(=O)(=O)NCCOCCOCCNC(=NCCCCN=C(NCCOCCOCCNS(=O)(=O)c3cccc(c3)[C@]4([H])CN(C)Cc5c4cc(cc5Cl)Cl)O)O)c6cc(cc(c6C1)Cl)Cl

InChI

InChIKey=DNHPDWGIXIMXSA-CXNSMIOJSA-N
InChI=1S/C50H66Cl4N8O10S2/c1-61-31-43(41-27-37(51)29-47(53)45(41)33-61)35-7-5-9-39(25-35)73(65,66)59-15-19-71-23-21-69-17-13-57-49(63)55-11-3-4-12-56-50(64)58-14-18-70-22-24-72-20-16-60-74(67,68)40-10-6-8-36(26-40)44-32-62(2)34-46-42(44)28-38(52)30-48(46)54/h5-10,25-30,43-44,59-60H,3-4,11-24,31-34H2,1-2H3,(H2,55,57,63)(H2,56,58,64)/t43-,44-/m0/s1

HIDE SMILES / InChI

Molecular Formula C50H66Cl4N8O10S2
Molecular Weight 1145.0525
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Tenapanor is an inhibitor of the sodium-proton (Na(+)/H(+)) exchanger NHE3 and reduces sodium absorption in the GI tract, thus increasing intestinal fluid. Ardelyx has completed Phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation (IBS-C) and submitted a new drug application to the U.S. Food and Drug Administration for the treatment of patients with IBS-C. In addition, tenapanor successfully completed phase III clinical trial for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and RDX013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease.

Approval Year

Doses

Doses

DosePopulationAdverse events​
50 mg 2 times / day multiple, oral
Recommended
Dose: 50 mg, 2 times / day
Route: oral
Route: multiple
Dose: 50 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Disc. AE: Diarrhea...
AEs leading to
discontinuation/dose reduction:
Diarrhea (6.5%)
Sources:
90 mg 2 times / day steady, oral
Highest studied dose
Dose: 90 mg, 2 times / day
Route: oral
Route: steady
Dose: 90 mg, 2 times / day
Sources:
healthy, mean 29.3 years
Health Status: healthy
Age Group: mean 29.3 years
Sex: M+F
Sources:
Other AEs: Diarrhea, Abdominal pain...
Other AEs:
Diarrhea (3 patients)
Abdominal pain (1 patient)
Headache (1 patient)
Sources:
180 mg single, oral
Highest studied dose
Dose: 180 mg
Route: oral
Route: single
Dose: 180 mg
Sources:
healthy, mean 37.5 years
Health Status: healthy
Age Group: mean 37.5 years
Sex: M+F
Sources:
60 mg 2 times / day steady, oral
Highest studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: steady
Dose: 60 mg, 2 times / day
Sources:
healthy, mean 37.5 years
Health Status: healthy
Age Group: mean 37.5 years
Sex: M+F
Sources:
Other AEs: Diarrhea...
Other AEs:
Diarrhea (1 patient)
Sources:
50 mg 2 times / day multiple, oral
Recommended
Dose: 50 mg, 2 times / day
Route: oral
Route: multiple
Dose: 50 mg, 2 times / day
Sources:
unhealthy, mean 45 years
Health Status: unhealthy
Age Group: mean 45 years
Sex: M+F
Sources:
Disc. AE: Diarrhea...
AEs leading to
discontinuation/dose reduction:
Diarrhea (6.5%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Diarrhea 6.5%
Disc. AE
50 mg 2 times / day multiple, oral
Recommended
Dose: 50 mg, 2 times / day
Route: oral
Route: multiple
Dose: 50 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Abdominal pain 1 patient
90 mg 2 times / day steady, oral
Highest studied dose
Dose: 90 mg, 2 times / day
Route: oral
Route: steady
Dose: 90 mg, 2 times / day
Sources:
healthy, mean 29.3 years
Health Status: healthy
Age Group: mean 29.3 years
Sex: M+F
Sources:
Headache 1 patient
90 mg 2 times / day steady, oral
Highest studied dose
Dose: 90 mg, 2 times / day
Route: oral
Route: steady
Dose: 90 mg, 2 times / day
Sources:
healthy, mean 29.3 years
Health Status: healthy
Age Group: mean 29.3 years
Sex: M+F
Sources:
Diarrhea 3 patients
90 mg 2 times / day steady, oral
Highest studied dose
Dose: 90 mg, 2 times / day
Route: oral
Route: steady
Dose: 90 mg, 2 times / day
Sources:
healthy, mean 29.3 years
Health Status: healthy
Age Group: mean 29.3 years
Sex: M+F
Sources:
Diarrhea 1 patient
60 mg 2 times / day steady, oral
Highest studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: steady
Dose: 60 mg, 2 times / day
Sources:
healthy, mean 37.5 years
Health Status: healthy
Age Group: mean 37.5 years
Sex: M+F
Sources:
Diarrhea 6.5%
Disc. AE
50 mg 2 times / day multiple, oral
Recommended
Dose: 50 mg, 2 times / day
Route: oral
Route: multiple
Dose: 50 mg, 2 times / day
Sources:
unhealthy, mean 45 years
Health Status: unhealthy
Age Group: mean 45 years
Sex: M+F
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no (co-administration study)
Comment: No significant inhibition or induction of CYP3A4 enzyme using midazolam as a substrate was observed when IBSRELA 50 mg was administered twice a day for 13 days in healthy subjects.
Page: 172
yes [IC50 0.4 uM]
no (co-administration study)
Comment: No significant inhibition or induction of CYP3A4 enzyme using midazolam as a substrate was observed when IBSRELA 50 mg was administered twice a day for 13 days in healthy subjects.
Page: 171
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
minor
yes (co-administration study)
Comment: Following co-administration of a single dose of IBSRELA 50 mg with repeated doses of itraconazole 200 mg, a CYP3A4 inhibitor, the mean AUC and Cmax of M1 was decreased 50% in healthy subjects
Page: 8
no
no
no
no
weak
weak
weak
weak
weak
weak
weak
yes
yes
Tox targets
Sourcing
PubMed

PubMed

TitleDatePubMed
Intestinal inhibition of the Na+/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans.
2014 Mar 12
Tenapanor hydrochloride for the treatment of constipation-predominant irritable bowel syndrome.
2015
Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.
2015 Jun
Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial.
2017 May
Patents

Sample Use Guides

twice-daily oral tenapanor (3, 10, or 30 mg [the latter down-titrated, if needed]) for 8 weeks
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Jun 26 14:08:31 UTC 2021
Edited
by admin
on Sat Jun 26 14:08:31 UTC 2021
Record UNII
WYD79216A6
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TENAPANOR
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
RDX-013 COMPONENT TENAPANOR
Common Name English
TENAPANOR COMPONENT OF RDX013
Common Name English
TENAPANOR [INN]
Common Name English
TENAPANOR [WHO-DD]
Common Name English
TENAPANOR [USAN]
Common Name English
N,N'-(10,17,-DIOXO-3,6,21,24-TETRAOXA-9,11,16,18-TETRAAZAHEXACOSANE-1,26-DIYL)BIS(((4S)-6,8-DICHLORO-2-METHYL-1,2,3,4-TETRAHYDROISOQUINOLIN-4-YL)BENZENESULFONAMIDE)
Common Name English
AZD-1722
Code English
TENAPANOR COMPONENT OF RDX-013
Common Name English
12,15-DIOXA-2,7,9-TRIAZAHEPTADECANAMIDE, 17-(((3-((4S)-6,8-DICHLORO-1,2,3,4-TETRAHYDRO-2-METHYL-4-ISOQUINOLINYL)PHENYL)SULFONYL)AMINO)-N-(2-(2-(2-(((3-((4S)-6,8-DICHLORO-1,2,3,4-TETRAHYDRO-2-METHYL-4-ISOQUINOLINYL)PHENYL)SULFONYL)AMINO)ETHOXY)ETHOXY)ETHY
Systematic Name English
RDX013 COMPONENT TENAPANOR
Common Name English
AZD1722
Code English
Classification Tree Code System Code
NCI_THESAURUS C78276
Created by admin on Sat Jun 26 14:08:31 UTC 2021 , Edited by admin on Sat Jun 26 14:08:31 UTC 2021
Code System Code Type Description
NCI_THESAURUS
C152555
Created by admin on Sat Jun 26 14:08:31 UTC 2021 , Edited by admin on Sat Jun 26 14:08:31 UTC 2021
PRIMARY
DRUG BANK
DB11761
Created by admin on Sat Jun 26 14:08:31 UTC 2021 , Edited by admin on Sat Jun 26 14:08:31 UTC 2021
PRIMARY
RXCUI
2199674
Created by admin on Sat Jun 26 14:08:31 UTC 2021 , Edited by admin on Sat Jun 26 14:08:31 UTC 2021
PRIMARY
DRUG CENTRAL
5349
Created by admin on Sat Jun 26 14:08:31 UTC 2021 , Edited by admin on Sat Jun 26 14:08:31 UTC 2021
PRIMARY
INN
9652
Created by admin on Sat Jun 26 14:08:31 UTC 2021 , Edited by admin on Sat Jun 26 14:08:31 UTC 2021
PRIMARY
LACTMED
Tenapanor
Created by admin on Sat Jun 26 14:08:31 UTC 2021 , Edited by admin on Sat Jun 26 14:08:31 UTC 2021
PRIMARY
FDA UNII
WYD79216A6
Created by admin on Sat Jun 26 14:08:31 UTC 2021 , Edited by admin on Sat Jun 26 14:08:31 UTC 2021
PRIMARY
CAS
1234423-95-0
Created by admin on Sat Jun 26 14:08:31 UTC 2021 , Edited by admin on Sat Jun 26 14:08:31 UTC 2021
PRIMARY
PUBCHEM
71587953
Created by admin on Sat Jun 26 14:08:31 UTC 2021 , Edited by admin on Sat Jun 26 14:08:31 UTC 2021
PRIMARY
EPA CompTox
1234423-95-0
Created by admin on Sat Jun 26 14:08:31 UTC 2021 , Edited by admin on Sat Jun 26 14:08:31 UTC 2021
PRIMARY
Related Record Type Details
BINDER->LIGAND
BINDING
SALT/SOLVATE -> PARENT
EXCRETED UNCHANGED
AMOUNT EXCRETED
FECAL
METABOLIC ENZYME -> SUBSTRATE
Tenapanor is a substrate of CYP3A4 and CYP3A5; however, none of the CYP enzymes was found to be responsible for ?25% of its overall elimination.
Related Record Type Details
IMPURITY -> PARENT
Tenapanor is a substrate of CYP3A4 and CYP3A5; however, none of the CYP enzymes was found to be responsible for ?25% of its overall elimination.
Related Record Type Details
ACTIVE MOIETY